Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Rolling NDA submission completed for CAM-2038 to treat opioid use disorder

July 20, 2017

MMRF selects Avista Pharma to manufacture component of opioid addiction vaccine

July 14, 2017

FDA grants orphan drug designation to ResQ's LipidRescue

June 16, 2017

Fennec launches European Named Patient Program for sodium thiosulfate

May 31, 2017

Selecta initiates phase I trial of nicotine vaccine candidate SELA-070

May 15, 2017

Embera NeuroTherapeutics' EMB-001 well tolerated in phase Ib cocaine interaction study

May 9, 2017

Cleveland BioLabs updates entolimod progress

April 18, 2017

Battelle and Nanotherapeutics form alliance on medical countermeasures

April 6, 2017

SRI International receives FDA clearance to evaluate novel oral formulation of Zn-DTPA

April 3, 2017

BARDA elects not to exercise options for AEOL-10150 development for ARS and DEARE

March 28, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...